OSUR on Nasdaq
ORASURE TECHNOLOGIES INC
American surgical and medical instruments and apparatus company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Anika Therapeutics, Inc., Intersect ENT or Beta Bionics, Inc., or pick any stock.
- TickerOSUR on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersBethlehem, Pennsylvania1
- Incorporated inDE2
- Business address220 E First St, Bethlehem, Pa 180152
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product And Services brought in 95% of the revenue ORASURE TECHNOLOGIES INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product And Services | $402.2M | $184.6M | $109.1M |
| Other Revenues | $3.2M | $1.2M | $6.0M |
Regions
United States brought in 68% of the revenue ORASURE TECHNOLOGIES INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $361.7M | $139.2M | $78.3M |
| Africa | $29.3M | $32.7M | $24.0M |
| Europe | $8.1M | $8.4M | $7.4M |
| Other Foreign Countries | $6.4M | $5.5M | $5.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue58¢$66.8M
- Research and development37¢$42.5M
- Other costs3¢$3.9M
- Income tax2¢$1.8M
Out of $115.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $115.0M | $185.8M | $405.5M |
| COST OF PRODUCTS AND SERVICES SOLD | $66.8M | $106.4M | $233.8M |
| Gross profit | $48.2M | $79.4M | $171.7M |
| Research and development | $42.5M | $26.0M | $33.7M |
| Sales and marketing | $26.1M | $31.0M | $36.3M |
| General and administrative | $47.7M | $46.2M | $58.2M |
| Loss on impairments | $0 | $4.4M | $10.8M |
| Change in the estimated fair value of acquisition-related contingent consideration | $4.6M | $0 | -$99.0K |
| Gain on sale of assets | -$725.0K | $0 | $0 |
| Total operating expenses | $120.2M | $107.6M | $139.0M |
| Operating (loss) income | -$72.0M | -$28.2M | $32.7M |
| OTHER INCOME | $7.4M | $12.2M | $23.6M |
| (Loss) income before income taxes and equity investment | -$64.6M | -$16.0M | $56.3M |
| INCOME TAX EXPENSE | $1.8M | $1.8M | $2.6M |
| (LOSS) INCOME BEFORE EQUITY INVESTMENT | -$66.4M | -$17.8M | $53.7M |
| LOSS ON EQUITY INVESTMENT | -$2.3M | -$1.7M | $0 |
| NET (LOSS) INCOME | -$68.7M | -$19.5M | $53.7M |
| Basic earnings per share (in US dollars per share) | -$0.94 | -$0.26 | $0.73 |
| Diluted earnings per share (in US dollars per share) | -$0.94 | -$0.26 | $0.72 |
| Basic weighted average number of shares outstanding (in shares) | 73.5M shares | 74.4M shares | 73.3M shares |
| Diluted weighted average number of shares outstanding (in shares) | 73.5M shares | 74.4M shares | 74.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $199.3M | $267.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $188 and $774 | $22.2M | $23.8M | $40.2M | |
| Inventories | $31.1M | $34.2M | ||
| Prepaid expenses | $5.2M | $4.0M | ||
| Other current assets | $4.1M | $3.5M | ||
| Total current assets | $261.9M | $333.2M | ||
| Property, plant and equipment, net of accumulated depreciation | $39.2M | $45.1M | ||
| Operating right-of-use assets, net | $12.0M | $13.4M | ||
| Finance right-of-use assets, net | $146.0K | $145.0K | ||
| Net | $19.0M | $17.4M | ||
| Goodwill | $43.4M | $40.3M | $35.7M | |
| Investment in equity method investee | $26.0M | $28.3M | ||
| Deferred tax asset | $271.0K | $156.0K | ||
| Other noncurrent assets | $1.3M | $1.5M | ||
| Total noncurrent assets | $141.3M | $146.4M | ||
| TOTAL ASSETS | $403.2M | $479.7M | ||
| Accounts payable | $6.5M | $8.2M | ||
| Deferred revenue | $1.5M | $3.0M | $1.6M | |
| Accrued expenses and other current liabilities | $11.1M | $20.2M | ||
| Finance lease liability | $63.0K | $41.0K | ||
| Operating lease liability | $2.2M | $2.1M | ||
| Current portion | $18.4M | $0 | ||
| Total current liabilities | $39.8M | $33.5M | ||
| Finance lease liability | $100.0K | $113.0K | ||
| Operating lease liability | $10.9M | $12.3M | ||
| Long-term portion | $9.3M | $22.9M | ||
| Other noncurrent liabilities | $2.2M | $494.0K | ||
| Total noncurrent liabilities | $22.5M | $35.8M | ||
| TOTAL LIABILITIES | $62.3M | $69.3M | ||
| Preferred stock, par value $0.000001, 25,000 shares authorized, none issued | $0 | $0 | ||
| Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding | $0 | $0 | ||
| Additional paid-in capital | $531.4M | $538.1M | ||
| Accumulated other comprehensive loss | -$18.4M | -$24.4M | ||
| Accumulated deficit | -$172.2M | -$103.4M | ||
| Total stockholders' equity | $340.8M | $410.3M | $430.7M | $364.4M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $403.2M | $479.7M | ||
| Allowance for doubtful accounts | $188.0K | $774.0K | $1.2M | |
| Preferred stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 70.4M shares | 74.6M shares | ||
| Common stock, shares outstanding (in shares) | 70.4M shares | 74.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $199.3M | $267.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $188 and $774 | $22.2M | $23.8M | $40.2M | |
| Inventories | $31.1M | $34.2M | ||
| Prepaid expenses | $5.2M | $4.0M | ||
| Other current assets | $4.1M | $3.5M | ||
| Total current assets | $261.9M | $333.2M | ||
| Property, plant and equipment, net of accumulated depreciation | $39.2M | $45.1M | ||
| Operating right-of-use assets, net | $12.0M | $13.4M | ||
| Finance right-of-use assets, net | $146.0K | $145.0K | ||
| Net | $19.0M | $17.4M | ||
| Goodwill | $43.4M | $40.3M | $35.7M | |
| Investment in equity method investee | $26.0M | $28.3M | ||
| Deferred tax asset | $271.0K | $156.0K | ||
| Other noncurrent assets | $1.3M | $1.5M | ||
| Total noncurrent assets | $141.3M | $146.4M | ||
| TOTAL ASSETS | $403.2M | $479.7M | ||
| Accounts payable | $6.5M | $8.2M | ||
| Deferred revenue | $1.5M | $3.0M | $1.6M | |
| Accrued expenses and other current liabilities | $11.1M | $20.2M | ||
| Finance lease liability | $63.0K | $41.0K | ||
| Operating lease liability | $2.2M | $2.1M | ||
| Current portion | $18.4M | $0 | ||
| Total current liabilities | $39.8M | $33.5M | ||
| Finance lease liability | $100.0K | $113.0K | ||
| Operating lease liability | $10.9M | $12.3M | ||
| Long-term portion | $9.3M | $22.9M | ||
| Other noncurrent liabilities | $2.2M | $494.0K | ||
| Total noncurrent liabilities | $22.5M | $35.8M | ||
| TOTAL LIABILITIES | $62.3M | $69.3M | ||
| Preferred stock, par value $0.000001, 25,000 shares authorized, none issued | $0 | $0 | ||
| Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding | $0 | $0 | ||
| Additional paid-in capital | $531.4M | $538.1M | ||
| Accumulated other comprehensive loss | -$18.4M | -$24.4M | ||
| Accumulated deficit | -$172.2M | -$103.4M | ||
| Total stockholders' equity | $340.8M | $410.3M | $430.7M | $364.4M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $403.2M | $479.7M | ||
| Allowance for doubtful accounts | $188.0K | $774.0K | $1.2M | |
| Preferred stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 70.4M shares | 74.6M shares | ||
| Common stock, shares outstanding (in shares) | 70.4M shares | 74.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$68.7M | -$19.5M | $53.7M |
| Stock-based compensation | $10.1M | $11.9M | $10.7M |
| Depreciation and amortization | $10.2M | $10.9M | $20.9M |
| Loss on impairments | $0 | $4.4M | $10.8M |
| Other non-cash amortization | -$222.0K | -$564.0K | $3.0K |
| Provision for credit losses | -$65.0K | $71.0K | -$462.0K |
| Unrealized foreign currency loss (gain) | $365.0K | -$263.0K | $103.0K |
| Interest expense on finance leases | $8.0K | $22.0K | $51.0K |
| Loss on equity investment | $2.3M | $1.7M | $0 |
| Deferred income taxes | $1.9M | -$657.0K | $102.0K |
| (Gain) loss on sale of fixed assets | -$725.0K | $563.0K | $0 |
| Change in the estimated fair value of acquisition-related contingent consideration | $4.6M | $0 | -$99.0K |
| Payment of acquisition-related contingent consideration | $0 | $0 | -$19.0K |
| Accounts receivable | $1.9M | $15.9M | $31.1M |
| Inventories | $3.6M | $13.1M | $48.2M |
| Prepaid expenses and other assets | -$2.4M | $4.1M | -$2.5M |
| Accounts payable | -$1.7M | -$7.6M | -$27.0M |
| Deferred revenue | -$1.5M | -$219.0K | -$730.0K |
| Accrued expenses and other liabilities | -$8.7M | -$6.4M | -$3.4M |
| Net cash (used in) provided by operating activities | -$49.0M | $27.4M | $141.6M |
| Purchases of short-term investments | $0 | -$53.2M | -$74.7M |
| Proceeds from maturities and redemptions of investments | $0 | $53.1M | $102.4M |
| Purchase of equity method investee | $0 | -$30.0M | $0 |
| Acquisition of business, net of cash acquired | -$3.6M | -$5.0M | $0 |
| Proceeds from sale of assets | $1.0M | $0 | $0 |
| Purchases of property and equipment | -$4.2M | -$3.8M | -$5.8M |
| Purchase of property and equipment under government contracts | $0 | $0 | -$4.5M |
| Proceeds from funding under government contracts | $0 | $0 | $48.7M |
| Net cash (used in) provided by investing activities | -$6.8M | -$39.0M | $66.2M |
| Cash payments for lease liabilities | -$61.0K | -$842.0K | -$1.3M |
| Proceeds from exercise of stock options | $0 | $214.0K | $269.0K |
| Repurchase of common stock | -$15.0M | $0 | $0 |
| Payment of acquisition-related contingent consideration | $0 | $0 | $46.0K |
| Payment of taxes related to net share settlement of equity awards | -$1.8M | -$3.5M | -$1.9M |
| Net cash used in financing activities | -$16.9M | -$4.2M | -$3.0M |
| EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH | $4.3M | -$6.8M | $1.7M |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | -$68.5M | -$22.6M | $206.4M |
No quarter-by-quarter statement was filed.
Leadership
Who has led ORASURE TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerManner Carrie Eglinton Jun 6, 2022 to now12
- PresidentKathleen Gallagher Weber Jan 7, 2022 to Feb 3, 202213
- PresidentLisa Nibauer Jan 7, 2022 to May 12, 202214
- PresidentManner Carrie Eglinton Jun 6, 2022 to now12
- Chief financial officerKenneth J. McGrath Aug 15, 2022 to now15
- Chief financial officerScott Gleason Sep 20, 2021 to May 24, 202216
- Chief financial officerRoberto Cuca Jun 11, 2018 to May 10, 202117
- Chief financial officerRonald H. Spair Jan 25, 2006 to Jun 11, 201818
- Chief operating officerRonald H. Spair Oct 3, 2006 to Jun 11, 201819
Board members and other officers (35)
- DirectorNancy J. Gagliano Apr 5, 2022 to Apr 5, 202220
- EVP & BU Lead - InfectiousLisa Nibauer May 13, 2020 to May 13, 202121
- EVP & BU Lead - MolecularKathleen Gallagher Weber Jan 4, 2019 to Mar 4, 202522
- VP, Finance and ControllerMichele Marie Miller Nov 2, 2018 to now23
- SVP, Research and DevelopmentEric Whitters Mar 4, 2014 to Feb 5, 201524
- EVP, Marketing and SalesAnthony Zezzo Ii. Jan 4, 2011 to Feb 4, 202025
- VP, Marketing and SalesManuel O. Mendez Nov 12, 2009 to Jan 27, 201026
- Exec. VP - Sales & Mktg.Joseph E. Zack Jan 25, 2006 to Feb 5, 200827
- VP & ControllerMark L. Kuna Jan 25, 2006 to Oct 24, 201828
- Exec. VP - OperationsP. Michael Formica Jan 25, 2006 to Aug 21, 200929
- Exec. VP and CSOStephen R. Lee Sep 26, 2006 to Feb 5, 201430
- Board memberJohn D. Bertrand May 14, 2026 to now31
- Board memberJohn P. Kenny Sep 10, 2024 to now32
- Board memberRobert W. McMahon Aug 1, 2023 to now33
- Board memberManner Carrie Eglinton Jun 6, 2022 to now12
- Board memberAnne Clem Whitaker Nov 10, 2021 to May 17, 202334
- Board memberNancy J. Gagliano Nov 23, 2021 to now35
- Board memberDavid Shulkin Apr 8, 2020 to now36
- Board memberLelio Marmora Jun 2, 2020 to now37
- Board memberJames A. Datin Aug 14, 2019 to May 16, 202438
- Board memberAradhana Sarin Feb 2, 2018 to May 22, 201939
- Board memberMara G. Aspinall Jun 22, 2017 to now40
- Board memberEamonn P. Hobbs Mar 23, 2016 to May 18, 202241
- Board memberGerald M. Ostrov Nov 14, 2011 to May 22, 201442
- Board memberCharles W. Patrick Jan 10, 2006 to May 19, 202043
- Board memberDouglas G. Watson Jan 25, 2006 to Nov 16, 201644
- Board memberFrank G. Hausmann Jan 25, 2006 to Feb 5, 200745
- Board memberRoger L. Pringle Jan 25, 2006 to May 17, 201746
- Board memberRonny B. Lancaster Jan 25, 2006 to Aug 29, 202247
- Board memberJack Goldstein May 23, 2006 to Feb 3, 201148
- Board memberRonald H. Spair Oct 3, 2006 to Jun 11, 201819
- Board memberMichael Celano Oct 5, 2006 to Aug 16, 202249
- General counselAgnieszka Gallagher Nov 30, 2021 to Feb 3, 202250
- General counselJack E. Jerrett Jan 25, 2006 to Jan 3, 202251
- General counselStephen R. Lee Jan 25, 2006 to Jan 25, 200652
Timeline
- Jun 6, 2022New chief executive Manner Carrie Eglinton becomes CEO12
Filings
314 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 144 insider forms, 37 large holders, 54 other. The latest 20:
- Oct 1, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 17, 2026SCHEDULE 13D EDGAR
- Sep 9, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 7, 2026S-8 EDGAR
- Aug 7, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jun 30, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 11, 20268-K EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 3, 20268-K EDGAR
- May 14, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- May 14, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- May 14, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
The 314 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
21 open-market trades by officers, directors and large owners since October 2021: 19 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $2.99 | $74.8K | Form 4 |
| May 13, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $3.02 | $75.5K | Form 4 |
| May 12, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $2.98 | $74.5K | Form 4 |
| Mar 20, 2026 | McGrath Kenneth JChief Financial Officer | Buy | 32,300 | $2.93 | $94.6K | Form 4 |
| Mar 20, 2026 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 32,300 | $2.93 | $94.6K | Form 4 |
| Mar 13, 2026 | McGrath Kenneth JChief Financial Officer | Buy | 22,021 | $3.00 | $66.1K | Form 4 |
| Mar 13, 2026 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 22,022 | $3.00 | $66.1K | Form 4 |
| Nov 28, 2025 | Gagliano Nancy JDirector | Buy | 2,100 | $2.37 | $5.0K | Form 4 |
| Feb 28, 2025 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 28,670 | $3.49 | $100.1K | Form 4 |
| Feb 27, 2025 | Gagliano Nancy JDirector | Buy | 12,750 | $3.08 | $39.3K | Form 4 |
| Feb 27, 2025 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 78,625 | $3.15 | $247.7K | Form 4 |
| Feb 27, 2025 | Kenny John P.Director | Buy | 47,659 | $3.17 | $151.1K | Form 4 |
| Feb 27, 2025 | McGrath Kenneth JChief Financial Officer | Buy | 64,000 | $3.15 | $201.6K | Form 4 |
| Feb 27, 2025 | Marmora LelioDirector | Buy | 7,000 | $3.06 | $21.4K | Form 4 |
| Dec 19, 2023 | Weber Kathleen GallagherChief Product Officer | Sale | 24,129 | $8.05 | $194.2K | Form 4 |
| Aug 15, 2023 | Anthony Michele MarieSVP Finance & CAO | Sale | 1,758 | $6.50 | $11.4K | Form 4 |
| May 30, 2023 | McGrath Kenneth JChief Financial Officer | Buy | 100,000 | $4.93 | $493.0K | Form 4 |
| Aug 26, 2022 | LANCASTER RONNY BDirector | Buy | 50,000 | $4.00 | $200.0K | Form 4 |
| Aug 25, 2022 | Aspinall Mara G.Director | Buy | 6,000 | $4.19 | $25.1K | Form 4 |
| Aug 17, 2022 | Gagliano Nancy JDirector | Buy | 2,200 | $4.39 | $9.7K | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Islet Management, LPSCHEDULE 13D, 1 filing Sep 17, 202653
- GAGNON SECURITIES LLCSCHEDULE 13G, 4 filings Nov 17, 2025 to Aug 12, 202654
- PRIVATE MANAGEMENT GROUP INCSCHEDULE 13G/A, 3 filings May 5, 2025 to Jul 31, 202655
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202656
- Altai Capital Management, L.P.SCHEDULE 13D/A, 5 filings Sep 9, 2025 to Apr 20, 202657
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202658
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G/A, 2 filings Feb 9, 2024 to Oct 9, 202559
- EARNEST PARTNERS LLCSCHEDULE 13G/A, 2 filings Feb 8, 2022 to Sep 3, 202560
- Camber Capital Management LPSCHEDULE 13G/A, 3 filings Nov 8, 2021 to May 15, 202561
- Neuberger BermanSCHEDULE 13G, 3 filings Oct 4, 2024 to Apr 4, 202562
- MANAGED ACCOUNT ADVISORS LLCSC 13G/A, 2 filings Jan 26, 2022 to Feb 7, 202363
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 6,256,762 | $27.9M | 0.0% | −259,454 |
| Neuberger Berman Group LLC | 4,685,432 | $20.9M | 0.0% | +323,531 |
| Private Management Group Inc | 3,797,682 | $16.9M | 0.4% | −1,624,447 |
| Vanguard Capital Management LLC | 3,018,907 | $13.5M | 0.0% | −11,981 |
| Systematic Financial Management LP | 2,857,974 | $12.7M | 0.3% | +377,491 |
| Dimensional Fund Advisors LP | 2,340,901 | $10.4M | 0.0% | −479,929 |
| First Eagle Investment Management, LLC | 2,125,500 | $9.5M | 0.0% | New |
| Renaissance Technologies LLC | 2,014,903 | $9.0M | 0.0% | −68,400 |
| Geode Capital Management, LLC | 1,807,889 | $8.1M | 0.0% | −12,130 |
| State Street Corp | 1,686,609 | $7.5M | 0.0% | −18,171 |
| Gagnon Securities LLC | 1,592,147 | $7.1M | 1.4% | −122,244 |
| Cannell Capital LLC | 1,427,419 | $6.4M | 4.4% | −575,852 |
| Gagnon Advisors, LLC | 1,207,440 | $5.4M | 3.4% | No change |
| Peapod Lane Capital LLC | 993,875 | $4.4M | 3.0% | −24,601 |
| Wells Fargo & Company/mn | 924,030 | $4.1M | 0.0% | +24,189 |
| Jacobs Levy Equity Management, Inc | 844,935 | $3.8M | 0.0% | −154,658 |
| D. E. Shaw & Co., Inc. | 827,187 | $3.7M | 0.0% | −555,201 |
| Archon Capital Management LLC | 747,909 | $3.3M | 1.4% | No change |
| Vanguard Portfolio Management LLC | 623,664 | $2.8M | 0.0% | +33,466 |
| Jpmorgan Chase & Co | 589,177 | $2.7M | 0.0% | +228,653 |
| Northern Trust Corp | 587,408 | $2.6M | 0.0% | −7,764 |
| Charles Schwab Investment Management Inc | 579,583 | $2.6M | 0.0% | −6,254 |
| Goldman Sachs Group Inc | 561,650 | $2.5M | 0.0% | +150,124 |
| Vanguard Fiduciary Trust Co | 458,067 | $2.0M | 0.0% | +3,292 |
| Tudor Investment Corp Et Al | 400,829 | $1.8M | 0.0% | +288,073 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARKathleen Gallagher Weber, President
- 14SEC EDGARLisa Nibauer, President
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARNancy J. Gagliano, Director
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARMark L. Kuna, VP & Controller
- 29
- 30SEC EDGARStephen R. Lee, Exec. VP and CSO
- 31SEC EDGARJohn D. Bertrand, Board member
- 32SEC EDGARJohn P. Kenny, Board member
- 33SEC EDGARRobert W. McMahon, Board member
- 34SEC EDGARAnne Clem Whitaker, Board member
- 35SEC EDGARNancy J. Gagliano, Board member
- 36SEC EDGARDavid Shulkin, Board member
- 37SEC EDGARLelio Marmora, Board member
- 38SEC EDGARJames A. Datin, Board member
- 39SEC EDGARAradhana Sarin, Board member
- 40SEC EDGARMara G. Aspinall, Board member
- 41SEC EDGAREamonn P. Hobbs, Board member
- 42SEC EDGARGerald M. Ostrov, Board member
- 43SEC EDGARCharles W. Patrick, Board member
- 44SEC EDGARDouglas G. Watson, Board member
- 45SEC EDGARFrank G. Hausmann, Board member
- 46SEC EDGARRoger L. Pringle, Board member
- 47SEC EDGARRonny B. Lancaster, Board member
- 48SEC EDGARJack Goldstein, Board member
- 49SEC EDGARMichael Celano, Board member
- 50SEC EDGARAgnieszka Gallagher, General counsel
- 51SEC EDGARJack E. Jerrett, General counsel
- 52SEC EDGARStephen R. Lee, General counsel
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63